Drug news
FDA requires two new trials for Iluvien(Alimera Sciences) for Diabetic Macular Oedema
The FDA now requires an additional two trials for Iluvien (fluocinolone acetonide) from Alimera Sciences before granting an approval for Diabetic Macular Oedema associated with Diabetic Retinopathy as the company has not provided sufficient data. This may mean a two year delay to American approval. Alimera Sciences plans to file in the UK this month.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.